Compare programs side by side

Medicationsemaglutidetirzepatide Dosage formInjectionODTSublingualOral Program typestandard-dosemicrodose

Comparison limit: four programs. Effective monthly cost includes required membership fees; prepaid plans show total due today. Statuses: see methodology v1.0.

Scope and definitions

This tool covers cash-pay compounded semaglutide and tirzepatide programs from tracked U.S. telehealth providers, using the same captured dataset that powers the pricing pages. Each card shows two prices for a reason. The month-to-month figure is the effective cost with no prepayment commitment. The lowest effective monthly figure is the best rate available on that program, which usually requires prepaying a multi-month term — a real discount that is also a real commitment, since the full term is due up front. Membership fees, where a provider charges them, are shown separately and are already included in the effective-cost figures, because a medication price without its mandatory membership isn't the real price.

How to use the filters

Start by fixing the two things that must match your situation: medication and dosage form. Then narrow by program type (standard dose versus microdose), membership tolerance, and budget. The cards re-sort by lowest effective monthly cost as you filter. Select up to four programs to open a side-by-side view with fees, shipping, dose-surcharge status, and any conflict notes. Resist comparing across the separations the tool preserves — a microdose price next to a standard-dose price isn't a discount, it's a different product.

Comparison methodology

The tool draws exclusively from our captured program database and applies the site's affordability methodology: it sorts by effective monthly cost (total mandatory cost ÷ months supplied), folds mandatory memberships and fees into that figure, and never merges programs across medication, dosage form, or program type into a single ordering. It excludes savings a general shopper can't reliably obtain — coupons, referral credits, tax-advantaged spending, insurance offsets — so the number you see is the one most people actually pay. Crucially, it does not rank: it orders captured figures by cost and shows each figure's evidence status, because a genuine ranking requires checkout-verified evidence that doesn't yet exist for any category. This keeps the tool useful for shortlisting without overstating what the data supports.

Reading the evidence status on each card

Every card carries a status pill, and it changes how much weight the number deserves. Provider Reported means the figure comes from the provider's own current page but hasn't been confirmed at checkout — the common case today. Independently Calculated means we did the arithmetic from captured inputs. Conflicting Evidence means reputable sources disagree or a claim contradicts itself, and that program is excluded from any eventual ranking until the conflict resolves. No card shows Verified yet, because checkout verification is still in progress — which is exactly why this tool helps you shortlist rather than handing you a winner.

What the captured market looks like

Across the tracked programs, three structural patterns shape any comparison you'll run. The lowest rankable effective monthlies cluster among long-term prepaid plans from all-inclusive providers, in the mid-$100s, which require twelve-month commitments and carry unverified renewal terms. Some providers advertise lower headlines but are excluded from rankings for approximate, dose-dependent, or conflicting pricing. The membership-model providers advertise lower medication prices that rise sharply once their required monthly fee is added, which is why the tool folds membership into the effective figure rather than showing the headline. And the coaching-heavy programs sit highest, because you're buying a service bundle, not just the molecule. Filtering by "no membership fee" tends to surface the all-inclusive providers; filtering by budget surfaces the prepaid plans. Neither filter substitutes for verifying that a low advertised figure survives checkout and holds at renewal — the two places low prices most often unravel.

Limitations

The comparison is only as current as the capture, and prices change between our snapshot and your checkout — the checkout total is always authoritative. Renewal pricing, cancellation terms, and state availability are largely uncaptured and aren't in the cards yet, so a program that looks cheapest month-to-month could carry an unfavorable renewal you can't see here. Providers pending capture don't appear at all; they're listed in the directory. Treat the tool as a structured starting point, then verify the specific program's full terms and dispensing pharmacy before committing.

Frequently asked questions

Why doesn't the tool tell me which is best?

Because "best" depends on facts we haven't verified yet — renewal pricing, cancellation fairness, pharmacy quality — and on what you personally weigh. The tool sorts by captured effective monthly cost and shows each figure's evidence status so you can shortlist honestly. A verified "best value" or "most affordable" ranking publishes only once at least three programs per category clear checkout verification.

Are the compared prices all-inclusive?

They include every disclosed mandatory charge, with membership fees folded into the effective-cost figure. Where a fee is undisclosed, we treat it as unverified rather than zero, so a card's number can be a floor. Always confirm the full checkout total, since that's the figure you actually pay.

Can I compare a microdose plan against a standard-dose plan?

The tool will display them together if you don't filter them apart, but you shouldn't treat that as apples-to-apples. Microdose and standard-dose programs are different products with different expected effects, and microdosing has no standardized definition or equivalent evidence base. Compare within a program type, not across.

Why do some providers show no membership fee and others do?

Providers use different business models: some bundle everything into the medication price, others charge a lower medication price plus a required monthly membership. Neither is inherently cheaper — a $99 medication with a $79 membership can cost more than a bundled $145. The effective-cost figure normalizes both so you compare real totals.

What the captured market looks like

Across the tracked programs, three business models explain almost all the price variation, and recognizing which one a provider uses tells you more than the headline. All-inclusive bundlers (NexLife, Henry Meds) quote a single monthly figure with no separate membership, so the advertised number is close to the true cost. Membership-plus-medication providers (Mochi, Ivím) advertise a low medication price beneath a required monthly fee, so the true cost is often 40–80% above the headline. Long-term prepaid discounters (including NexLife's own 12-month plans) offer the lowest per-month rates but require the full term up front. The comparison tool folds membership into the effective figure precisely so these three models can be read on one scale — otherwise a membership provider's headline looks deceptively competitive against a bundler's.

How to read across the three separations

The tool never merges programs across the three lines the methodology keeps separate, and neither should your comparison. Semaglutide and tirzepatide have different price floors (tirzepatide runs roughly $30–$100/month higher at the same provider), so a cross-medication comparison is meaningless. Injections, ODT, and sublingual forms have different — and for compounded products, largely uncharacterized — absorption, so a lower oral price is not a discount on an injection. And standard-dose versus microdose is a different product entirely, not a cheaper tier of the same thing. Filter to one medication, one form, and one program type, then compare effective monthly cost within that set; that is the only comparison the evidence supports.

Effective cost, worked across models

A concrete example shows why the normalization matters. A membership provider advertising "$99/month" semaglutide with a required $79 membership has an effective monthly cost of $178 — higher than a bundler advertising a flat "$145/month" with no membership, even though the membership provider's headline is $46 lower. A long-term prepaid plan advertising, say, $130/month looks cheapest of all, but that rate requires paying the full year up front, against refund terms that are usually unverified. The tool surfaces all three numbers — headline, effective monthly, and (via the linked calculators) amount due today — so the cheapest-looking option and the genuinely cheapest option can be told apart.